XTL Biopharmaceuticals Valuation

Is XTLB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XTLB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XTLB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XTLB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XTLB?

Key metric: As XTLB is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for XTLB. This is calculated by dividing XTLB's market cap by their current book value.
What is XTLB's PB Ratio?
PB Ratio	8.3x
Book	US$2.71m
Market Cap	US$22.44m

XTLB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-26.4x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does XTLB's PB Ratio compare to its peers?

The above table shows the PB ratio for XTLB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	10.3x
GRAC Grace Breeding	33.9x	n/a	₪67.9m
GFC-M G.F.C Green Fields Capital	0.7x	n/a	₪115.4m
CANF Can-Fite BioPharma	5.7x	41.6%	₪53.1m
CBI Clal Biotechnology Industries	0.9x	n/a	₪55.8m
XTLB XTL Biopharmaceuticals	8.3x	n/a	₪84.0m

Price-To-Book vs Peers: XTLB is good value based on its Price-To-Book Ratio (8.3x) compared to the peer average (10.3x).

Price to Book Ratio vs Industry

How does XTLB's PB Ratio compare vs other companies in the Asian Biotechs Industry?

10 Companies	Price / Book	Estimated Growth	Market Cap

10 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: XTLB is expensive based on its Price-To-Book Ratio (8.3x) compared to the Asian Biotechs industry average (2.7x).

Price to Book Ratio vs Fair Ratio

What is XTLB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XTLB PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	8.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate XTLB's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Evogene

₪34.8m

Operates as a computational biology company.

EVGN

₪6.48

-5.3%

-73.2%

Protalix BioTherapeutics

US$112.5m

A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

PLX

US$7.33

-0.1%

97.5%